Roche immunotherapy combination increases lung cancer survival-study – Reuters
Reuters |
Roche immunotherapy combination increases lung cancer survival-study
Reuters (Reuters) – Roche's immunotherapy Tecentriq, given with its older drug Avastin and chemotherapy, improved survival of advanced lung cancer patients by about 30 percent over the combination without Tecentriq, according to interim results of a late stage … |
